InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026)
InMed Pharmaceuticals (INM) posted quarterly Change in Accured Expenses of $113837.0 for Q1 2026, up 270.87% year-over-year from $30694.4 in Q1 2025, and up 295.1% quarter-over-quarter from -$58348.0 in Q4 2025.
InMed Pharmaceuticals (INM) Change in Accured Expenses (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals' Change in Accured Expenses history runs 8 years deep, the most recent figure standing at $113837.0 for Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 270.87% year-over-year to $113837.0; the TTM figure through Mar 2026 stood at -$118906.0 (down 198.0% YoY), while the FY2025 annual figure was -$249728.0, down 651.5% from the prior year.
- Change in Accured Expenses for Q1 2026 stood at $113837.0, up from -$58348.0 in the prior quarter.
- The five-year high for Change in Accured Expenses was $470728.0 in Q2 2024, with the low at -$642392.0 in Q3 2024.
- The 5-year median for Change in Accured Expenses is -$104340.0 (2024), against an average of -$137505.2.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses slumped 253.19% in 2023, then jumped 312.82% in 2024.
- InMed Pharmaceuticals' Change in Accured Expenses stood at -$349611.0 in 2022, then jumped by 169.04% to $241378.0 in 2023, then jumped by 48.98% to $359614.0 in 2024, then slumped by 116.23% to -$58348.0 in 2025, then surged by 295.1% to $113837.0 in 2026.
- Business Quant data shows INM's Change in Accured Expenses at $113837.0 in Q1 2026, -$58348.0 in Q4 2025, and -$274066.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn | 82.00 Mn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn | 142.00 Mn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn | -219.00 Mn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn | -4.00 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | -8.50 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.48 Mn | 1.24 Mn | - | 113,837.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 113,837.00 |
| Mar 31, 2026 | 113,837.00 |
| Dec 31, 2025 | -58,348.00 |
| Dec 31, 2025 | -58,348.00 |
| Sep 30, 2025 | -274,066.00 |
| Sep 30, 2025 | -274,066.00 |
| Jun 30, 2025 | 99,671.00 |
| Jun 30, 2025 | 99,671.00 |
| Mar 31, 2025 | -66,621.00 |
| Mar 31, 2025 | -66,621.00 |
| Dec 31, 2024 | 359,614.00 |
| Dec 31, 2024 | 359,614.00 |
| Sep 30, 2024 | -642,392.00 |
| Sep 30, 2024 | -642,392.00 |
| Jun 30, 2024 | 470,728.00 |
| Jun 30, 2024 | 470,728.00 |
| Mar 31, 2024 | -104,340.00 |
| Mar 31, 2024 | -104,340.00 |
| Dec 31, 2023 | 241,378.00 |
| Dec 31, 2023 | 241,378.00 |